Prediction of Early Neurological Deterioration in Individuals With Minor Stroke and Large Vessel Occlusion Intended for Intravenous Thrombolysis Alone.


Journal

JAMA neurology
ISSN: 2168-6157
Titre abrégé: JAMA Neurol
Pays: United States
ID NLM: 101589536

Informations de publication

Date de publication:
01 03 2021
Historique:
pubmed: 12 1 2021
medline: 12 1 2022
entrez: 11 1 2021
Statut: ppublish

Résumé

The best reperfusion strategy in patients with acute minor stroke and large vessel occlusion (LVO) is unknown. Accurately predicting early neurological deterioration of presumed ischemic origin (ENDi) following intravenous thrombolysis (IVT) in this population may help to select candidates for immediate transfer for additional thrombectomy. To develop and validate an easily applicable predictive score of ENDi following IVT in patients with minor stroke and LVO. This multicentric retrospective cohort included 729 consecutive patients with minor stroke (National Institutes of Health Stroke Scale [NIHSS] score of 5 or less) and LVO (basilar artery, internal carotid artery, first [M1] or second [M2] segment of middle cerebral artery) intended for IVT alone in 45 French stroke centers, ie, including those who eventually received rescue thrombectomy because of ENDi. For external validation, another cohort of 347 patients with similar inclusion criteria was collected from 9 additional centers. Data were collected from January 2018 to September 2019. ENDi, defined as 4 or more points' deterioration on NIHSS score within the first 24 hours without parenchymal hemorrhage on follow-up imaging or another identified cause. Of the 729 patients in the derivation cohort, 335 (46.0%) were male, and the mean (SD) age was 70 (15) years; of the 347 patients in the validation cohort, 190 (54.8%) were male, and the mean (SD) age was 69 (15) years. In the derivation cohort, the median (interquartile range) NIHSS score was 3 (1-4), and the occlusion site was the internal carotid artery in 97 patients (13.3%), M1 in 207 (28.4%), M2 in 395 (54.2%), and basilar artery in 30 (4.1%). ENDi occurred in 88 patients (12.1%; 95% CI, 9.7-14.4) and was strongly associated with poorer 3-month outcomes, even in patients who underwent rescue thrombectomy. In multivariable analysis, a more proximal occlusion site and a longer thrombus were independently associated with ENDi. A 4-point score derived from these variables-1 point for thrombus length and 3 points for occlusion site-showed good discriminative power for ENDi (C statistic = 0.76; 95% CI, 0.70-0.82) and was successfully validated in the validation cohort (ENDi rate, 11.0% [38 of 347]; C statistic = 0.78; 95% CI, 0.70-0.86). In both cohorts, ENDi probability was approximately 3%, 7%, 20%, and 35% for scores of 0, 1, 2 and 3 to 4, respectively. The substantial ENDi rates observed in these cohorts highlights the current debate regarding whether to directly transfer patients with IVT-treated minor stroke and LVO for additional thrombectomy. Based on the strong associations observed, an easily applicable score for ENDi risk prediction that may assist decision-making was derived and externally validated.

Identifiants

pubmed: 33427887
pii: 2774466
doi: 10.1001/jamaneurol.2020.4557
pmc: PMC7802007
doi:

Substances chimiques

Fibrinolytic Agents 0
Tissue Plasminogen Activator EC 3.4.21.68

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

321-328

Investigateurs

Sonia Alamowitch (S)
Charles Arteaga (C)
Omar Bennani (O)
Yves Berthezene (Y)
Marion Boulanger (M)
Claire Boutet (C)
Serge Bracard (S)
Nicolas Bricout (N)
Hervé Brunel (H)
Serkan Cakmak (S)
Mohamed Chbicheb (M)
Frédéric Clarençon (F)
Vincent Costalat (V)
Audrey Courselle-Arnoux (A)
Séverine Debiais (S)
Mathilde Delpech (M)
Christian Denier (C)
Hubert Desal (H)
Olivier Detante (O)
Gauthier Duloquin (G)
Laurie Fraticelli (L)
Sébastien Gazzola (S)
Jan Gralla (J)
Valer Grigoras (V)
Benoit Guillon (B)
Matthieu Krug (M)
Steven Hajdu (S)
Simon Jung (S)
Frédéric Klapczynski (F)
Didier Leys (D)
François Lun (F)
Arnaud Malbranque (A)
Sébastien Marcel (S)
Patrik Michel (P)
Jean-Louis Mas (JL)
Mylène Masson (M)
Norbert Nighoghossian (N)
Michael Obadia (M)
Catherine Oppenheim (C)
Canan Ozsancak (C)
Fernando Pico (F)
Michel Piotin (M)
Christine Pires (C)
Sébastien Richard (S)
Yves Samson (Y)
Isabelle Serre (I)
Igor Sibon (I)
Philippe Smadja (P)
Laurent Spelle (L)
Laurent Suissa (L)
Serge Timsit (S)
Emmanuel Touzé (E)
Amélie Tuffal (A)
Anne-Evelyne Vallet (AE)
Marion Yger (M)
Stéphane Vannier (S)
Mathieu Zuber (M)

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Auteurs

Pierre Seners (P)

Neurology Department, GHU Paris psychiatrie et neurosciences, Institut de Psychiatrie et Neurosciences de Paris, INSERM U1266, Université de Paris, FHU Neurovasc, Paris, France.

Wagih Ben Hassen (W)

Radiology Department, GHU Paris psychiatrie et neurosciences, Institut de Psychiatrie et Neurosciences de Paris, INSERM U1266, Université de Paris, FHU Neurovasc, Paris, France.

Bertrand Lapergue (B)

Neurology Department, Foch University Hospital, Suresnes, France.

Caroline Arquizan (C)

Neurology Department, CHRU Gui de Chauliac, Montpellier, France.

Mirjam R Heldner (MR)

Neurology Department, Inselspital, University Hospital, University of Bern, Bern, Switzerland.

Hilde Henon (H)

Neurology Department, CHU Lille, Université de Lille, INSERM U1171, Lille, France.

Claire Perrin (C)

Neurology Department, GHU Paris psychiatrie et neurosciences, Institut de Psychiatrie et Neurosciences de Paris, INSERM U1266, Université de Paris, FHU Neurovasc, Paris, France.

Davide Strambo (D)

Stroke Center, Neurology Service, CHU Vaudois, Lausanne University, Lausanne, Switzerland.

Jean-Philippe Cottier (JP)

Neurology Department, Bretonneau Hospital, Tours, France.

Denis Sablot (D)

Neurology Department, Perpignan Hospital, Perpignan, France.

Isabelle Girard Buttaz (I)

Neurology Department, Valenciennes Hospital, Valenciennes, France.

Ruben Tamazyan (R)

Neurology Department, Saint Joseph Hospital, Paris, France.

Cécile Preterre (C)

Neurology Department, Nantes University Hospital, Nantes, France.

Pierre Agius (P)

Neurology Department, Nantes University Hospital, Nantes, France.
Neurology Department, St Nazaire Hospital, Saint-Nazaire, France.

Nadia Laksiri (N)

Neurology Department, La Timone University Hospital, Marseille, France.

Laura Mechtouff (L)

Department of Stroke Medicine, Hospices Civils de Lyon, Lyon, France.

Yannick Béjot (Y)

Neurology Department, Dijon University Hospital, Dijon, France.

Duc-Long Duong (DL)

Neurology Department, Versailles University Hospital, Versailles, France.

François Mounier-Vehier (F)

Neurology Department, Lens Hospital, Lens, France.

Gioia Mione (G)

Neurology Department, Nancy University Hospital, Nancy, France.

Charlotte Rosso (C)

Sorbonne Université, Institut du Cerveau et de la Moelle épinière, ICM, INSERM U 1127, CNRS UMR 7225, AP-HP, Urgences Cérébro-Vasculaires, ICM Infrastructure Stroke Network, Hôpital Pitié-Salpêtrière, Paris, France.

Ludovic Lucas (L)

Stroke Unit, Bordeaux University Hospital, Bordeaux, France.

Jérémie Papassin (J)

Stroke Unit, Grenoble University Hospital, Grenoble, France.
Neurology Department, Centre Hospitalier Metropole-Savoie, Chambery, France.

Andreea Aignatoaie (A)

Neurology Department, Centre Hospitalier Régional d'Orléans, Orléans, France.

Aude Triquenot (A)

Neurology Department, CHU Rouen, Rouen, France.

Emmanuel Carrera (E)

Neurology Department, Geneve University Hospital, Geneve, Switzerland.

Philippe Niclot (P)

Neurology Department, René Dubos Hospital, Pontoise, France.

Alexandre Obadia (A)

Neurology Department, Fondation Adolphe de Rothschild, Paris, France.

Aïcha Lyoubi (A)

Neurology Department, Delafontaine Hospital, Saint-Denis, France.

Pierre Garnier (P)

Stroke Unit, Saint-Etienne University Hospital, Saint-Etienne, France.

Nicolae Crainic (N)

Neurology Department, Brest University Hospital, Brest, France.

Valérie Wolff (V)

Neurology Department, Strasbourg University Hospital, Strasbourg, France.

Clément Tracol (C)

Neurology Department, Rennes University Hospital, Rennes, France.

Frédéric Philippeau (F)

Neurology Department, Fleyriat Hospital, Bourg-en-Bresse, France.

Chantal Lamy (C)

Neurology Department, Amiens University Hospital, Amiens, France.

Sébastien Soize (S)

Neuroradiology Department, Reims University Hospital, Reims, France.

Jean-Claude Baron (JC)

Neurology Department, GHU Paris psychiatrie et neurosciences, Institut de Psychiatrie et Neurosciences de Paris, INSERM U1266, Université de Paris, FHU Neurovasc, Paris, France.

Guillaume Turc (G)

Neurology Department, GHU Paris psychiatrie et neurosciences, Institut de Psychiatrie et Neurosciences de Paris, INSERM U1266, Université de Paris, FHU Neurovasc, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH